Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 3,993 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now directly owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $15.91 on Wednesday. The firm has a 50-day moving average of $15.38 and a 200-day moving average of $19.20. Tyra Biosciences, Inc. has a one year low of $12.34 and a one year high of $29.60. The company has a market cap of $805.05 million, a P/E ratio of -9.88 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Tyra Biosciences

A number of hedge funds have recently bought and sold shares of TYRA. Franklin Resources Inc. purchased a new stake in shares of Tyra Biosciences during the 3rd quarter valued at $278,000. Valence8 US LP purchased a new stake in Tyra Biosciences during the third quarter worth about $310,000. SG Americas Securities LLC bought a new stake in Tyra Biosciences in the third quarter worth about $311,000. The Manufacturers Life Insurance Company purchased a new position in Tyra Biosciences in the third quarter valued at about $333,000. Finally, HighVista Strategies LLC bought a new position in shares of Tyra Biosciences during the 2nd quarter valued at approximately $257,000. 84.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $22.00 to $31.00 in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, January 13th. UBS Group assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.